英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
spheroides查看　spheroides　在百度字典中的解释百度英翻中〔查看〕
spheroides查看　spheroides　在Google字典中的解释Google英翻中〔查看〕
spheroides查看　spheroides　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Fovinaciclib for First-Line Therapy of Advanced Breast Cancer
    Published Online: June 1, 2026 doi:10 1001 jamaoncol 2026 1938 Corresponding Author: Binghe Xu, MD, PhD, Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, 17 Panjianyuan Nanli, Beijing 100021, China (xubinghe@medmail com cn)
  • Fovinaciclib for first-line therapy of advanced breast cancer
    Media advisory: This study is being presented at the 2026 American Society of Clinical Oncology Annual Meeting
  • Fovinaciclib for first-line therapy of advanced breast cancer
    Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and
  • Fovinaciclib for First-Line Therapy of Advanced Breast Cancer: A . . .
    Adding fovinaciclib to first-line aromatase inhibitor conferred significant and clinically meaningful PFS benefit and consistent improvements in other efficacy outcomes, along with manageable safety and unaffected quality of life Importance Approximately 70% of patients with breast cancer (BC) have hormone receptor-positive, human epidermal growth factor receptor 2 (ERBB2; formerly HER2
  • JAMA Oncology – Cancer Treatment, Genetics, Prevention
    Lifestyle and Metformin Interventions and Risk of Multimorbidity in Adults With Prediabetes Original Investigation June 15, 2026 Most Viewed
  • 复星医药子公司奥鸿药业复妥宁 III期研究成果亮相2026 ASCO . . .
    该研究成果全文于6月1日同步发表于JAMA Oncology (5年平均影响因子：24 7)，全球首次全面公布 复星医药（HK2196） 控股子公司锦州奥鸿药业有限责任公司 (简称：奥鸿药业)自主研发的创新型小分子CDK4 6抑制剂枸橼酸伏维西利胶囊 (商品名：复妥宁)：一线治疗激素受体 (HR)阳性、人表皮生长因子受体2 (HER2)阴性晚期乳腺癌Ⅲ期研究的期中分析数据。 研究结果显示，在一线内分泌治疗方案基础上联用复妥宁，可显著延长患者无进展生存期 (PFS) (HR=0 55，95%CI:0 38–0 77;单侧p=0 0003)，其余各项疗效指标同步改善，整体安全性表现良好 [1]。
  • Add on Fovinaciclib to First-Line Hormone Therapy Improves Outcomes in . . .
    Researchers have found in a randomized clinical trial that addition of fovinaciclib to first-line aromatase inhibitor therapy significantly improved progression-free survival and enhanced other efficacy outcomes The combination demonstrated a manageable safety profile and did not adversely affect patients' quality of life The study was published in JAMA Oncology by Peng Y and colleagues
  • Fovinaciclib for first-line therapy of advanced breast cancer
    "Fovinaciclib for first-line therapy of advanced breast cancer " Brightsurf News, Jun 1 2026, https: www brightsurf com news 1WR4Q32L fovinaciclib-for-first-line-therapy-of-advanced-breast-cancer html Copy
  • Fovinaciclib for First-Line Therapy of Advanced Breast . . .
    如果求助人在 48 小时内还未确认，系统默认应助成功，本求助将自动关闭。
  • 行业动态 |复宏汉霖创新CDK4 6抑制剂复妥宁两项III期研究 . . .
    复宏汉霖创新CDK4 6抑制剂复妥宁®两项III期研究成果亮相， 一线研究同期登载 JAMA Oncology PPS 2026年美国临床肿瘤学会（ASCO）年会于5月29日至6月2日在芝加哥顺利举办。





中文字典-英文字典  2005-2009